Hoefer Welker designs Kansas' first facility for alternative cancer treatment
Hoefer Welker designed the new treatment facility within the University of Kansas Health System, one of only 38 proton therapy centers in the U.S. It's scheduled to open in January.
AbstractCardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to directly relate to cardiac radiation dose and to stem from a range of cellular pathways that are often related to fibrosis. The importance of minimizing radiation dose to the heart is especially critical in the pediatric population and when treating disease sites adjacent to the heart. Proton therapy ...
Proton pencil beam scanning (PBS) represents an interesting option for the treatment of breast cancer (BC) patients with nodal involvement. Here we compare tangential 3D-CRT and VMAT to PBS proton therapy (PT)...
Purpose: In selected breast cancer (BC) patients, proton therapy (PrTh) has the potential to lower radiation doses to heart, lung and contralateral breast (CLB) compared to photon therapy. However, higher skin toxicity using PrTh has been reported in literature. We prospectively evaluated acute toxicity in breast cancer patients treated with robust intensity modulated proton therapy (IMPT).
Breast radiotherapy is associated with an increased risk of ischemic heart disease, particularly for left-sided irradiation due to direct anatomical proximity between the left anterior descending coronary artery (LADCA) and the target volumes [1 –4]. First generation radiotherapy techniques, which relied on wide treatment fields, were associated with a substantial cardiac mortality increase. Fortunately, breast irradiation has benefited from recent technological progresses allowing significant cardiac sparing, such as intensity-modulated radiation therapy (IMRT) , proton therapy  or deep-inspiration breath hold (DIBH).
First, and perhaps most importantly, Dinh et al are to be applauded for presenting their prospective series of men treated with proton therapy at the University of Washington and their carefully reported rectal toxicity outcomes in the context of dose-volume histogram analysis as well as differing rectal immobilization devices.1 These result s provide strong evidence suggesting that without the use of a rectal spacer, there is increased rectal toxicity with proton therapy compared with intensity modulated radiation therapy (IMRT).
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinomas (ICC) are the most prevalent intrahepatic primary cancer and the second leading cause of cancer death [Petrick2016], [Hong2016], [Igaki2017]. Although biologically and clinically distinct entities, both share common management issues.
CONCLUSION: We designed and clinically applied a technique for the treatment of liver cancer with proton pencil beam scanning in forced deep expiration breath-hold. The initial data on plan robustness and patient positioning suggest that the choices in terms of planning technique and treatment margins are able to reach the desired balance between target coverage and organ at risk sparing. PMID: 32976870 [PubMed - as supplied by publisher]
CONCLUSION: Robustly optimized PBS-PT for cervical cancer patients shows equivalent target robustness against inter- and intra-fraction variability compared to VMAT, and offers significantly better OAR sparing. PMID: 32956707 [PubMed - as supplied by publisher]
One out of thirty cancer patients worldwide is diagnosed with cervical cancer  and the 5-year overall survival rate for the early stage group is 91% . Half of all diagnosed cervical cancer patients is younger than 35 years , whereby late radiation-induced toxicities have a large influence on quality of life . Thus, prevention of late radiation-induced side effects becomes increasingly relevant.
Conclusions: Normal tissue sparing was achieved regardless of patient age for infratentorial tumours. However, for supratentorial tumours, there was a dosimetric advantage of IMPT across 9 vs. 13-year-old patients.